Article Text

PDF
Short report
Factors associated with partner notification of STIs in men who have sex with men on PrEP in France: a cross-sectional substudy of the ANRS-IPERGAY trial
  1. Marie Suzan-Monti1,2,
  2. Laurent Cotte3,
  3. Lisa Fressard1,2,
  4. Eric Cua4,
  5. Catherine Capitant5,
  6. Laurence Meyer5,
  7. Gilles Pialoux6,
  8. Jean-Michel Molina7,
  9. Bruno Spire1,2
  10. On behalf of the ANRS IPERGAY Study Group
  1. 1Aix-Marseille University, INSERM, IRD, SESSTIM, Marseille, France
  2. 2ORS PACA, Southeastern Health Regional Observatory, Marseille, France
  3. 3Department of Infectious Diseases, Hôpital de la Croix Rousse, INSERM U1052, Lyon, France
  4. 4Department of Infectious Diseases, Hôpital de l’Archet, Centre Hospitalier de Nice, Nice, France
  5. 5INSERM SC10 US19, Villejuif, France
  6. 6Department of Infectious Diseases, Hospital Tenon, Assistance Publique Hôpitaux de Paris, Paris, France
  7. 7Department of Infectious Diseases, Hospital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
  1. Correspondence to Dr Marie Suzan-Monti, Aix-Marseille University, INSERM, IRD, SESSTIM, Marseille 13005, France; marie.suzan{at}inserm.fr

Abstract

Objectives Partner notification (PN) is a useful public health approach to enhance targeted testing of people at high risk of HIV and other STIs, and subsequent linkage to care for those diagnosed. In France, no specific PN guidelines exist and information about current practices is scarce. We used the ANRS-IPERGAY PrEP trial to investigate PN in HIV-negative men who have sex with men (MSM) reporting a bacterial STI.

Methods This substudy included 275 participants who completed a specific online PN questionnaire during the open-label extension study of the ANRS-Intervention Préventive de l’Exposition aux Risques avec et pour les Gays (IPERGAY) trial. Variables used as proxies of at-risk practices were defined using data collected at the previous follow-up visit about participants’ most recent sexual encounter and preventive behaviours. χ2 or Fisher’s exact test helped select variables eligible for multiple logistic models.

Results Of the 275 participants, 250 reported at least one previous STI. Among the latter, 172 (68.8%) had informed their partner(s) of their most recent STI. Of these, 138 (80.2%) and 83 (48.3%) had notified their casual and main partners, respectively. Participants were less likely to notify their main partner when their most recent sexual encounter involved unsafe anal sex with a casual partner (adjusted OR (aOR) (95% CI) 0.18 (0.06 to 0.54), P=0.02). Older participants were less likely to inform casual partners (aOR (95% CI) 0.44 (0.21 to 0.94), P=0.03), while those practising chemsex during their most recent sexual encounter were more likely to inform their casual partners (aOR (95% CI) 2.56 (1.07 to 6.09), P=0.03).

Conclusion Unsafe sexual encounters with people other than main partners and street drugs use were two sociobehavioural factors identified, respectively, as a barrier to main PN and a motivator for casual PN, in a sample of high-risk MSM. These results provide an insight into current PN practices regarding STI in France and might inform future decisions about how to define feasible and acceptable PN programmes.

  • behavioural science
  • gay men
  • infectious diseases
  • partner notification

Statistics from Altmetric.com

Footnotes

  • Handling editor Jackie A Cassell

  • Contributors MS-M participated in the data analysis and interpretation of results and wrote the first draft of the manuscript. LF performed the statistical analyses. LC, EC, CC, LM, J-MM and BS participated in the interpretation of results and contributed to reviewing the manuscript. LC and EC were also involved in the design of the substudy. All authors approved the final version of the manuscript.

  • Funding The ANRS IPERGAY trial was sponsored by the ANRS (France Recherche Nord & Sud Sida-HIV Hepatites), and funded by ANRS, the Canadian HIV Trials Network, the Fonds de dotation Pierre Bergé pour la Prévention - SIDACTION, and the Bill & Melinda Gates Foundation.

  • Competing interests None declared.

  • Ethics approval The ANRS IPERGAY trial was approved by public health authorities and by ethics committees in France (Comité de Protection des Personnes Ile de France IV, n°2011/26) and Canada (Comité d’Ethique de la Recherche de Montréal, CTN268).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Collaborators The ANRS IPERGAY Study Group: J-M Molina (coordinator), C Capitant, B Spire, G Pialoux, L Cotte, I Charreau, C Tremblay, J-M Le Gall, E Cua, A Pasquet, F Raffi, C Pintado, C Chidiac, J Chas, P Charbonneau, C Delaugerre, M Suzan-Monti, B Loze, J Fonsart, G Peytavin, A Cheret, J Timsit, G Girard, N Lorente, M Préau, JF Rooney, MA Wainberg, D Thompson, W Rozenbaum, V Doré, L Marchand, M-C Simon, N Etien, J-P Aboulker, L Meyer and J-F Delfraissy.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.